logo
What Happened to Suki Waterhouse? Hernia Diagnosis Explained

What Happened to Suki Waterhouse? Hernia Diagnosis Explained

Yahoo16-07-2025
recently revealed via social media that she was diagnosed with a hernia. The 33-year-old is currently scheduled for a stage performance on August 8, 2025, in Aspen, Colorado, as part of the Up in the Sky music festival. Following this, she will launch the U.K. and European leg of her The Sparklemuffin tour, which will conclude on August 31, 2025. She will then support Laufey in the A Matter of Time tour between September and October.
Here is what we have learned about Waterhouse's hernia diagnosis.
Suki Waterhouse took to X (formerly Twitter) to reveal why she had not been very active on the platform for the past few months. The singer shared that she had gotten a hernia six months ago after wearing very 'tight' pants.
She also shared two accompanying pictures. The first one saw her posing under some green foliage. She wore a white coat and crop top, which she paired with tight pants. Meanwhile, the second photo showed the actress-singer wearing a hospital gown, wristband, and earphones, while lying on the bed. She also had a vape lying on her chest in the second image.
''Suki you never tweet anymore' have you ever considered I wore pants so tight 6 months ago it caused a hernia & I've been too scared to tell you,' the Daisy Jones & The Six star wrote on the platform.
Fans reacted to the post in a myriad of ways, with many highlighting the vape present on her chest in the second picture.
'Vape in the hospital is diabolical,' a fan wrote. To which, Waterhouse responded, 'So true.'
'Girl what is wrong with you,' another tweeted. They added, 'You cant vape in your hospital room and if you are in the hospital you clearly shouldnt be for your health either.'
A fan also expressed fear about Waterhouse's condition, commenting, 'Don't scare me like that.' They subsequently expressed hope that the Assassination Nation actress would recover.
According to the Cleveland Clinic, a hernia typically occurs in the abdomen or groin. It happens when one of the organs pushes through a muscle or tissue containing it. It manifests as a bulge that can come and go during different activities or in various positions. Symptoms of a hernia include discomfort and pain. It will need to be remedied through surgery.
The post What Happened to Suki Waterhouse? Hernia Diagnosis Explained appeared first on ComingSoon.net - Movie Trailers, TV & Streaming News, and More.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Who is Karrueche Tran? Meet the actress who might be dating Deion Sanders.
Who is Karrueche Tran? Meet the actress who might be dating Deion Sanders.

USA Today

time3 hours ago

  • USA Today

Who is Karrueche Tran? Meet the actress who might be dating Deion Sanders.

Hall of Famer and Colorado head coach Deion Sanders spent Monday revealing his bladder cancer battle that included a shoutout to Randy Moss for support... and some jokes about Porta Potties on the sideline. It was all good news for Sanders, who will keep coaching Colorado this season. After that lengthy press conference? There was another possible revelation: A video showing Karrueche Tran by his side hit the interwebs and people wondered if she and Sanders were dating. While we have no confirmation about whether she and he are a couple or not, people are wondering who she is. We have answers! Let's dive in: Who is Karrueche Tran? She's an actress who has been on Claws and The Bay, the latter of which earned her a Daytime Emmy. She's from Los Angeles and she's also been called a socialite. She's done some red carpet reporting as well as hosting. What is Karrueche Tran's dating history? She dated singer Chris Brown and then she dated ex-New York Giants wideout Victor Cruz. is Karrueche Tran dating Deion Sanders? Again, no official word on that yet. This is all we have: So... we'll see!

SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results

Yahoo

time5 hours ago

  • Yahoo

SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results

NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1130215. The archived webcast will be available in the Investor Relations section of the Company's website. About SIGA SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world's most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit Contacts:Suzanne Harnettsharnett@ and Investors Media Jennifer Drew-Bear, Edison GroupJdrew-bear@ Holly Stevens, CG Lifehstevens@

Sarepta shares rebound after shipments of gene therapy Elevidys resume in US
Sarepta shares rebound after shipments of gene therapy Elevidys resume in US

Yahoo

time5 hours ago

  • Yahoo

Sarepta shares rebound after shipments of gene therapy Elevidys resume in US

(Reuters) -Sarepta Therapeutics shares surged more than 30% before the bell on Tuesday, as analysts said the resumption of U.S. shipments for its muscular gene therapy partially removes financial headwinds and decreases the risk of market withdrawal. The company said on Monday it would resume shipments of Elevidys — approved in the U.S. to treat a rare condition called Duchenne muscular dystrophy — to patients who can walk. U.S. shipments to patients who cannot walk independently are still halted, following the death of two teenage boys earlier this year. These incidents brought heightened regulatory scrutiny to Sarepta in recent weeks, while the pause of shipments raised concerns about the future of Elevidys — the company's largest revenue generator. Sarepta's announcement followed the U.S. Food and Drug Administration's recommendation that the voluntary hold on shipments be removed after a probe showed the death of an 8-year-old boy in Brazil was not related to Elevidys. Wall Street analysts said the resumption of shipments would allow Sarepta to fulfill its near-term payments to partner Arrowhead and maintain access to its debt facilities. "The FDA's recommendation and the resumption of commercial treatment in the U.S. virtually eliminate the risk of Elevidys being formally withdrawn from the market," said William Blair analyst Sami Corwin. While the decision allows some patients to regain access to the treatment, analysts warned that patients and doctors could show hesitancy in light of the recent hit to reputation. "It remains to be seen how the news headlines regarding the patient deaths will affect commercial interest in the near term," Corwin said. Sarepta's partner Roche had also stopped Elevidys shipments in certain countries outside the U.S. Shares of Sarepta surged 36% to $18.85 in premarket trading. They have fallen more than 80% since the first Elevidys-related death was reported in March. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store